BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol 2018;29:2037-45. [PMID: 30101284 DOI: 10.1093/annonc/mdy309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Pilco-Janeta DF, García-Valverde A, Gomez-Peregrina D, Serrano C. Emerging drugs for the treatment of gastrointestinal stromal tumors. Expert Opin Emerg Drugs 2021;26:53-62. [PMID: 33645383 DOI: 10.1080/14728214.2021.1896704] [Reference Citation Analysis]
2 Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res 2019;79:994-1009. [PMID: 30630822 DOI: 10.1158/0008-5472.CAN-18-1888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Tang F, Tie Y, Wei YQ, Tu CQ, Wei XW. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. Biochim Biophys Acta Rev Cancer 2021;1876:188606. [PMID: 34371128 DOI: 10.1016/j.bbcan.2021.188606] [Reference Citation Analysis]
4 Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, Chi P. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. Oncologist 2019;24:1309-e983. [PMID: 31213500 DOI: 10.1634/theoncologist.2019-0418] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
5 Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol 2020;38:3294-303. [PMID: 32804590 DOI: 10.1200/JCO.20.00522] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
6 Qianyi W, Mei X, Rui Z, Yong W, Yutao W, Xiaoding S, Xiaoting W. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study. J Cancer Res Clin Oncol 2021. [PMID: 34319443 DOI: 10.1007/s00432-021-03749-6] [Reference Citation Analysis]
7 Heymann D. Metastatic osteosarcoma challenged by regorafenib. Lancet Oncol 2019;20:12-4. [PMID: 30477938 DOI: 10.1016/S1470-2045(18)30821-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019;79:994-1009. [PMID: 30630822 DOI: 10.1158/0008-5472] [Cited by in F6Publishing: 161] [Reference Citation Analysis]
9 Liang X, Wu Z, Shen S, Niu Y, Guo Y, Liang J, Guo W. LINC01980 facilitates esophageal squamous cell carcinoma progression via regulation of miR-190a-5p/MYO5A pathway. Arch Biochem Biophys 2020;686:108371. [PMID: 32325088 DOI: 10.1016/j.abb.2020.108371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
10 Kong Q, Li G, Yin G, Li K, Zhang D, Xu W. Long Noncoding RNA WDFY3-AS2 Represses the Progression of Esophageal Cancer through miR-18a/PTEN Axis. J Oncol 2021;2021:9951010. [PMID: 34194502 DOI: 10.1155/2021/9951010] [Reference Citation Analysis]
11 Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923-34. [PMID: 32511981 DOI: 10.1016/S1470-2045(20)30168-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 23] [Article Influence: 29.5] [Reference Citation Analysis]
12 Ravegnini G, Sammarini G, Moran S, Calice G, Indio V, Urbini M, Astolfi A, Zanotti F, Pantaleo MA, Hrelia P, Angelini S. Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets. Cancer Manag Res 2019;11:6229-44. [PMID: 31308757 DOI: 10.2147/CMAR.S189661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Wu Z, Li Y, Niu Y, Lu J, Yan Z, Xu T, Guo Y, Dong Z, Guo W. FOXD3 suppresses epithelial-mesenchymal transition through direct transcriptional promotion of SMAD7 in esophageal squamous cell carcinoma. Mol Carcinog 2021;60:859-73. [PMID: 34551139 DOI: 10.1002/mc.23350] [Reference Citation Analysis]
14 Nishida T, Yoshinaga S, Takahashi T, Naito Y. Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors. Cancers (Basel) 2021;13:3158. [PMID: 34202544 DOI: 10.3390/cancers13133158] [Reference Citation Analysis]
15 Damele L, Ottonello S, Mingari MC, Pietra G, Vitale C. Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance? Cancers (Basel) 2020;12:E774. [PMID: 32218226 DOI: 10.3390/cancers12040774] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Ren L, Qian H, Wang J, Jin P, Hu Q, Yu J, Zhang X, Zhang Y, Huang H. A Serosa-Originated Gastric Stromal Tumor Misdiagnosed by Ultrasonography and Frozen Section Pathology: A Case Report. Onco Targets Ther 2020;13:5831-5. [PMID: 32606793 DOI: 10.2147/OTT.S257013] [Reference Citation Analysis]